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The Global Fund is experiencing increased pressure to optimize results and improve its impact per dollar spent. It is
also in transition from a provider of emergency funding, to a long-term, sustainable financing mechanism. This
paper assesses the efficacy of current Global Fund investment and examines how health technology assessments
(HTAs) can be used to provide guidance on the relative priority of health interventions currently subsidized by the
Global Fund. In addition, this paper identifies areas where the application of HTAs can exert the greatest impact
and proposes ways in which this tool could be incorporated, as a routine component, into application, decision,
implementation, and monitoring and evaluation processes. Finally, it addresses the challenges facing the Global
Fund in realizing the full potential of HTAs.
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Global healthIntroduction
The Global Fund, created in 2001 as a global financing
mechanism, enables low-income countries (LICs) and mid-
dle income countries (MICs) to promote access to certain
health interventions and technology for the prevention and
treatment of HIV/AIDS, tuberculosis, and malaria. Given
the commitment from its donors—amounting to almost
$30.5 billion in pledges and $24 billion in contributions to
date—as well as its scale of work in approximately 100
countries [1], the Global Fund has emerged as one of the
most significant global health players over the last decade.
Its total disbursements in 2009 constituted 3.29% of total
health expenditure in LICs, 0.22% in low MICs and 0.07%
in high MICs, while its contribution to individual coun-
tries ranged from 0.002% in Botswana to 53.4% in the
Democratic Republic of Congo [2].
As a global health financier rather than a technical or
implementing institution, the Global Fund does not op-
erate directly within countries or implement its own
programs [3]. Historically, the Global Fund has issued* Correspondence: yot.t@hitap.net.
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distribution, and reproduction in any medium“calls for proposals” for applications through a rounds-
based mechanism. As of August 2012, there have been
10rounds. At the time of writing, this system is in the
process of being replaced by a funding model allowing
for more flexible timing of grant applications. Global
Fund affiliated partnerships—termed Country Coordin-
ating Mechanisms (CCMs)—are tasked with developing
proposals based on stakeholder consultations, local
funding needs, and epidemiological context. The Global
Fund notes that the applicant is responsible for “decid-
ing their own priorities, strategies and programs.” Pro-
posals are submitted to the Secretariat, verified for
eligibility, and reviewed for completeness by a Technical
Review Panel (TRP), which in turn makes funding rec-
ommendations to the Global Fund Board. The TRP con-
sists of representatives with an array of expertise, both
scientific and programmatic, as well as program experi-
ence in HIV/AIDS, tuberculosis and/or malaria. The
TRP terms of reference direct the panel to review grant
applications against technical criteria including feasibil-
ity, value for money, and sustainability [3].
If a proposal is approved, funds can be disbursed
under the supervision of the CCM to the Principal Re-
cipients (PRs) and/or Sub-Recipient(s) (SRs) who areed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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addition, a Local Fund Agent (LFA), an independent
body contracted by the Global Fund Secretariat, is re-
sponsible for monitoring the PR’s performance, grant
implementation, and financial reports. Global Fund
grants can be made for a period of up to five years, al-
though funds are typically reviewed after two years, with
continued funding conditional upon performance [3]
and other factors [4].
As donor funding for global health declines due to the
global recession, the Global Fund is experiencing in-
creased pressure to optimize results and improve impact
per dollar spent [1]. In its recent strategic plan [5] cover-
ing the 2012–2016 period, the Global Fund sets ambi-
tious goals to increase impact by investing strategically
in areas with high potential and offering strong value for
money. Despite its clear objectives on “maximizing im-
pact and value for money,” there are still major chal-
lenges in the implementation of the plan. This paper
reviews the current successes and impediments of Glo-
bal Fund investment and examines how health technol-
ogy assessment (HTA) can be used to provide guidance
on the relative priority of health interventions (medica-
tions, devices, diagnostics, and other treatment modal-
ities) subsidized by the Global Fund. In addition, this
paper aims to identify areas where the application of
HTA could have the greatest impact and to propose
ways in which it could be incorporated, as a routine
component, into application, decision, implementation,
and monitoring and evaluation processes. Finally, it ad-
dresses the challenges facing the Global Fund in realiz-
ing the full potential of HTA.
The improved performance, transparency, and efficiency
of the Global Fund
As of 2013, the Global Fund has disbursed a total of
over $20 billion in 151 countries [6]. Its investments
have likely contributed to the significant increase in the
number of HIV/AIDS patients receiving antiretroviral
treatment (from an estimated 300,000 in 2002to 5.25
million by 2009 [7]) as well as the number of
insecticide-treated nets (ITNs) distributed in 35 high-
burden African countries (from an estimated 10 million
in 2004 to 35-44million per year between 2006 and 2008
[5]), as well as the detection rate of new smear-positive
tuberculosis cases (from 36%– 44% in 2000 to 55%–67%
in 2008 [8]).
The Global Fund is governed in a unique way, both at
a board and implementation level. Leadership is sourced
from within developing counties, the private-for-profit
sector, and civil society. There is a strong commitment
to increasing transparency and accountability, and as a
result, the fund has improved the availability and accur-
acy of information related to the disbursement offunding and coverage of specific services, including the
establishment of specific surveillance of the focal dis-
eases, despite difficulties involving duplication of infor-
mation systems in some recipient countries [7]. In
addition, the Global Fund has pursued the principle of
performance-based funding that is disbursement of
funds has been largely correlated with grant perform-
ance; for example, the best performing programs receiv-
ing 79% of their grant sums compared to 38% for the
worst performers [9].
Although there is an argument that performance-
based funding systems might place LICs at a disadvan-
tage due to their comparatively poor access to resources
and capacity, at least three studies have rejected this hy-
pothesis [2,10,11]. These studies reveal that when taking
other factors into consideration, grants in LICs have
tended to out-perform their more resource-rich counter-
parts. Lu and colleagues [10] reported that an increase
in per-capita income from $1000 to $2000 is associated
with a substantial reduction in disbursement of 2-year
grant sums (an indicator of both expenditure and
performance, in view of the Global Fund’s incremental
disbursement system). Radelet and Siddiqi [11] demon-
strated a similarly strong negative relation between the
income and achievement of programmatic targets. The
authors concluded that poor nations, including so-called
fragile states, had proven themselves capable of effect-
ively utilizing increased funding flows from the Global
Fund. Moreover, the most important finding is a signifi-
cant negative association between grant implementation
rates and income per person, suggesting that LICs are
more likely to disburse grants from the Global Fund
than countries with higher per capita income.
Although the Global Fund has dedicated itself to in-
creasing prevention and control of AIDS, tuberculosis,
and malaria, it has also made significant investments in
improving the health systems of LICs [12]. Flexibility of
the financial support from the Global Fund allows re-
cipient countries to strengthen their health systems
through a number of approaches, ranging from health
worker training sessions and salary support to improved
workforce retention and electronic health records sys-
tems. Such efforts may not only facilitate the success of
AIDS, tuberculosis, and malaria programs, but also en-
sure that scarce health system resources are not diverted
to these three diseases at the expense of other health
needs. In 2009, 35% of its funding contributed directly
to supporting human resources, infrastructure and
equipment, and monitoring and evaluation in health sys-
tems [13]. AIDS treatment programs themselves benefit
from investment in health systems, as healthcare
workers benefit directly from improved systems and in-
creased access to antiretroviral treatment results in
fewer patient admissions to hospital, which then helps
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can be devoted to other health needs [13].
The impediments and challenges
As with a number of global health initiatives, including
the GAVI Alliance, the policies and priorities of the Glo-
bal Fund are defined at a global level. Although the Glo-
bal Fund works to maintain relatively high levels of
national ownership in its programming, evidence sug-
gests that there remains misalignment between its pol-
icies and programs and those of national governments.
As a result, services that are managed both by the gov-
ernment and the Global Fund are often badly coordi-
nated and inefficiently managed, with duplication of
tasks—including reporting, monitoring and evaluation,
and funding/disbursement mechanisms—representing
significant obstacles to efficiency [12,14]. Delays in dis-
bursement of funds to the PRs and donor short falls in fi-
nancial pledges have both emerged as significant
challenges [1]. The significant fall in donor funding in the
2011–2013 funding round led directly to the cancelation
of the eleventh call for proposals. As a result of these is-
sues, efficiency improvement has been defined as a central
tenet of the Global Fund strategic plan for 2012–2016.
Several studies have identified efficiency shortfalls
within the Global Fund. At a macro-level, Zhao et al.
[15] reviewed performance indicators for Global Fund
malaria programs and identified an over reliance on in-
put indicators—especially those related to training activ-
ities—at the expense of outcome or impact indicators,
which are better suited to measuring disease reduction.
This tendency to set inappropriate indicators may distort
performance ratings and, consequently, grant funding
[15]. This has been seen in Timor-Leste, where effective
strategies for controlling malaria receive less funding
than behavioral change activities, despite the fact the
former approach has been found to be more effective in
disease prevention [16]. For instance, both ITN distribu-
tion programs (which have been found to be very effect-
ive in preventing malaria in high transmission areas
[17]) and case management (improved diagnosis), an-
other highly effective intervention, were clearly under-
financed, receiving less than 1% of the total grant
support [16], in favor of behavioral change programs.
This situation is repeated across HIV and tuberculosis
programs. Effective and efficient prevention and control
depend on implementing the right mix of interventions
for each setting and assuring the necessary coverage of
those interventions. Bridge et al. [18] found that less than
half HIV proposals funded by the Global Fund included
harm reduction activities, even though many studies con-
firm that these activities offer good value for money
[19,20]. Moreover, although there is strong evidence that
male circumcision can reduce HIV transmission in menby up to 60% [21], we found that no Global Fund pro-
posals included circumcision initiatives. At the same time,
many interventions that aim to influence knowledge, atti-
tudes, and beliefs and influence psychological and social
correlates of risk have received significant support from
the Global Fund [22], despite the fact that the impact of
these programs—including whether they bring about
sustained long-term behavior change—remains uncertain
[23]. Korenromp et al. [24] suggest that the Global Fund
could significantly enhance the impact of its tuberculosis
investment by reevaluating its investment across regions,
for instance by prioritizing investment in Africa, and by
screening and treating tuberculosis in populations with
high levels of HIV infection. A recent report developed by
the Value for Money Working Group (2013) reaffirmed
the limitations of the Global Fund’s investments in the TB,
HIV/AIDS and Malaria programs and it also provided
suggestions to improve funding strategies.
Aside from the issue of effectiveness, an increasing
amount of information on resource use and health conse-
quences, i.e. cost-effectiveness, has been amassed in recent
years. Global health professionals no longer focus only on
effective prevention and treatment; instead, more sophisti-
cated models that examine cost-effectiveness and com-
parative effectiveness as a way of improving public health
without requiring significantly more funding are at the
centre of most public health initiatives. The differences in
cost-effectiveness between interventions can be staggering,
particularly when considering initiatives that require im-
plementation at scale. For instance, despite massive in-
creases in access to HIV treatment, WHO and UNAIDS
estimate that, as of 2011,there are still as many as 15 mil-
lion people around the world in need of antiretroviral
therapy. To treat populations of this scale, the difference
in cost-effectiveness between the most cost-effective treat-
ment option and the least can be as much as 1,400 fold
(Disease Control Priorities in Developing Countries Pro-
ject) [25]. Even differences in intervention implementation
can result in significant variation. A 2011 paper by Amole
et al. [26] found that some Global Fund recipient coun-
tries are not currently optimizing their HIV treatment by
selecting the most cost-effective antiretroviral regimen
and implementation strategy (i.e. treating population who
is most likely to further transmit HIV infection to other
populations). Adjusting the current make-up of antiretro-
viral drug purchases in sub-Saharan Africa and India could
yield over $300 million in savings over the next five years
and expand the provision of quality services in resource
limited settings.
Despite the Global Fund’s explicit commitment to
implementing cost-effective and proven initiatives, it is
clearly failing to fund programs that fulfill these criteria
to the extent that it should. This may be because the
Global Fund provides support to countries based on
Teerawattananon et al. Globalization and Health 2013, 9:35 Page 4 of 9
http://www.globalizationandhealth.com/content/9/1/35requests received from CCMs, who themselves may not
have a clear idea about a country’s needs or the most
cost-effective strategies that can be implemented to meet
those needs. As a funding organization, the Global Fund
has little in-house technical capacity and little direct en-
gagement with countries to which they provide funding.
There is no systematic support to PRs on whether pro-
posed interventions are among the most effective and
cost-efficient for achieving the desired outcome in a given
context. Although the TRP has been set up to provide
funding recommendations to the Board of the Global Fund
for making final decisions, it is difficult for the TRP to as-
sess technical soundness and value for money or to make
rational recommendations on strategic investments based
only on the data presented in the applications, especially
when the information is weak, patchy, or inconsistent, and
where funding is limited to specific time periods. More-
over, an absence of guideline on what information should
be used in order to assess value for money and a lack of
HTA capacity of the TRP secretariat prohibit the use of
value for money information in TRP review process.
Furthermore, it is widely accepted that the impact and
cost-effectiveness of interventions depends to a large ex-
tent on the strength of the health system within which
they are delivered. A lack of absorptive capacity at all
levels of grant implementation has been identified in many
settings and may explain the slow progress in grant imple-
mentation outside of a robust health system [16,27]. Previ-
ous research on this subject reveals that inadequate
institutional capacity and high staff turn-over negatively
impacts organizational capacity, which can lead to poor
performance in both project implementation and monitor-
ing and evaluation [28-33]. Therefore, the Global Fund
needs to ensure that relevant infrastructure, e.g. laboratory
for HIV and CD4 test, is built before investment in com-
modities, e.g. antiretroviral drugs, are made. On the other
hand, HTA focus on effectiveness (real-work effect) of in-
vestment rather than efficacy (potential effect in idea situ-
ation) so that weakness at system level can be taken into
account appropriately in decision making process.
The situation can also be applied to the substantial in-
vestments in health information systems for improving
healthcare services and enhancing management, monitor-
ing and evaluation of the fund itself. Until now, very few
studies have addressed this issue [34,35]. As a result, HTA
on health information systems should be one of priority
areas given that there is very little evidence of a compre-
hensive plan by the Global Fund in this area or attempts
to standardize on a small number of well-established sys-
tems or to initiate any evaluations of such systems.
Potential applications of HTA within the Global Fund
As is made clear in The Global Fund strategy 2012–
2016, the organization must make the transition from anemergency funder to a long-term, sustainable financing
mechanism. To this end, it needs to develop new risk-
management approaches, strengthen internal governance,
institute a new grant-approval process, strengthen deci-
sion making by middle management, and improve its
focus on results [5]. Although this report does not provide
direction on certain critical issues that will define the fu-
ture success and impact of the Global Fund, it suggests
that the Global Fund could achieve better value for money
with better technical evaluation and management.
A 2011 report [36] by the Results for Development Insti-
tute on behalf of the Global Fund’s Market Dynamics Com-
mittee makes several recommendations for the optimization
of product selection, including that the Global Fund com-
mission global value for money guidance on specific prod-
ucts: “An experienced independent expert body such as the
National Institute for Health and Clinical Excellence (NICE)
could be commissioned to conduct robust comparative cost-
effectiveness analyses of two or more WHO-recommended
products and provide that information to the Global Fund
and its recipients.” This is not the first time that academics
have urged the Global Fund to consider the use of HTA to
improve its cost-effectiveness [25]. The application of an
HTA to a health initiative is a multidisciplinary activity that
systematically examines the costs and benefits as well as the
organizational implications and social consequences of the
application of a health policy and/or technology. HTAs often
function as a “bridges” between evidence and policy-making,
providing health policy-makers with accessible, useable, and
evidence-based information that can help guide their deci-
sions regarding the appropriate use of technology [37].
HTAs not only generate a wide range of policy-relevant
information that can aid decision making, but also em-
power stakeholders that are involved in the decision mak-
ing process. This is because HTAs, as tools in a priority
setting approach, are often designed according to a set of
questions that themselves encourage a critical evaluation
of the relevant social and financial factors [38]. This kind
of evaluation can help decision makers unpack evidence
and assess the relative importance of both process values
(such as transparency, accountability, participation, legal-
ity, faithfulness to constitutional provisions, and respect
for international obligations) and content values (such as
clinical effectiveness, value for money, equity, solidarity,
and feasibility). HTAs are particularly suitable for global
organizations because they take into account the kinds of
values that vary across settings as a result of differing so-
cial factors, including politics, culture, social demograph-
ics, religion, and levels of economic development.
Figure 1 is a modified version of the Global Fund’s
model of performance-based funding. It presents a
method for enhancing the efficiency of Global Fund pro-
jects, through the use of HTA. HTAs can enhance value
for money at all stages of the Global Fund process, from
Figure 1 Potential use of Health Technology Assessment (HTA) to enhance value for money of Global Fund initiatives.
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with the inclusion of an HTA, proposals are far more
likely to take into account cost and efficiency, among
other factors, resulting in a much higher quality, rigor-
ous, and evidence-based proposal. The higher the quality
of the proposal submitted to the Global Fund, the more
likely the donors will be to respond to the sustained level of
demand for resources. In other words, the higher the quality
of the proposal, the greater the impact obtained from invest-
ment. However, this task is not simple. Proposal develop-
ment requires an increased focus on intervention or mixes
of interventions that are locally appropriate, including as-
sessments of affordability and cost-effectiveness in the given
context. Cost-effectiveness information may be derived from
the existing literature, including the Disease Control Prior-
ities in Developing Countries project [17], as well as from
the Global Fund’s value for money guidance—a collective
set of comparable cost-effectiveness information of various
interventions implemented in various settings. This supports
the claim of Korenromp et al. [24] that proactive approaches
from the Global Fund to inform demand on the kinds of ini-
tiatives that yield good value for money (and those that do
not) would result in larger numbers of lives saved than
might be the case with the prevailing funding model, which
relies heavily on country demand.
We suggest not only that cost-effective interventions be
selected correctly from the value for money guidance, but
also that HTA be applied to at least some aspects of a pro-
posal before implementation. These ex-ante HTAs would
use existing evidence and assumptions to estimate the likely
costs and impacts of the proposed program (Table 1).
Having HTA as a pre-condition may well drive local data
generation through countries’ initiative and also by the Glo-
bal Fund. Relevant stakeholders should work with HTA ex-
perts to ensure the local relevancy of the assessment, as
well as to strengthen the absorptive capacity of the grant
recipients by facilitating the consideration of important pa-
rameters (factors) affecting the potential success of grant
implementation. The results of these ex-ante HTA can then
also be used as a baseline for conducting monitoring and
evaluation once the program is implemented. An ex-anteassessment can be used as a requirement for a CCM that
does not select the cost-effective interventions in its pro-
posal to demonstrate that the selected intervention(s) is at
least as cost-effective in a given context if not more so than
those reported in the value for money guidance. It is also
expected that this approach will help create shared prior-
ities of the Global Fund and its recipients.
HTAs are not only recommended at the pre-
implementation stage, they are also effective monitoring
and evaluation tools. Even though interventions may be
primarily designed to take into account context-specific is-
sues, it is essential that examinations be carried out to de-
termine whether they work well and remain efficient in
practice, particularly when implemented together with
other interventions within and outside Global Fund pro-
grams. Unlike ex-ante assessments, on-going HTAs can
take into account primary research and focus on context-
dependent issues, e.g. willingness of target populations to
participate in the program, adherence to intervention
protocol by providers and end-users, or other sectors’ re-
sponses to the program (Table 1). These kinds of HTAs
should also pay particular attention to the key surrogate
outcome indicators identified in the ex-ante assessment. It
is also possible that results from the ex-ante assessment
be used as benchmarks for the assessment at this stage.
Lastly, it is advised that HTA be included as part of the
final report that all CCMs submit to the Global Fund
when a particular program comes to an end. This should
help the Global Fund incorporate feedback mechanisms
regarding the requirements, constraints, and potential of
the PR and SRs, who will ultimately determine if the
Global Fund will achieve its goals. Collective information
on the value for money of various programs implemented
in different settings (value for money guidance) will be a
valuable resource for the Global Fund and other develop-
ment agencies in making future resource allocation deci-
sions. An equally important implication is that ex-post
HTA can provide information to various responsible au-
thorities in recipient countries to encourage them to con-
tinue financing programs that are proven to be good value
for money. As sustainability is a serious concern for all
Table 1 Examples of ex-ante and ex-post health technology assessments
A case study of ex-ante assessment of the feasibility and value for
money of the maternal and child health voucher scheme in
Myanmar [39]
A case study of an on-going HTA of HIV prevention for the most-
at-risk population in Thailand [40]
An ex-ante assessment was conducted as part of a collaborative
study undertaken by Myanmar’s Ministry of Health, WHO, and the
Thai Ministry of Public Health between March 2010 and September
2011. The aim of the assessment was to collect information to
guide the formulation and implementation of a demand-side
financing mechanism for maternal and child health (MCH) services
in Myanmar. The main objective of the MCH voucher scheme is to
eliminate the financial barriers to maternal and child health care
among poor households by providing support in the form of four
antenatal visits, delivery by skilled birth attendants, postnatal care,
transportation, food, and lodging. Using both qualitative and
quantitative methods, including an economic evaluation, this
collaborative research demonstrates that the use of demand-side
financing for MCH services in Myanmar appears to be feasible and
represents good value for money. The evidence suggested that the
initiative was likely to garner support from community leaders and
civic groups, and be accepted by target populations and health
workers, because it removes many of the impediments that people
currently Figure 1 Potential use of Health Technology Assessment
(HTA) to enhance value for money of Global Fund initiatives.
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encounter when trying to access MCH services. Some of the most
common barriers that people face when trying to access these
services are the long distances between the residence of the
mother and the nearest health facility, and the related high
travelling costs (particularly in rural areas), the high cost of
medicines (which for many is unaffordable).
Global Fund for a (Round 8) grant support of $75.46 million over
five years, from July 2009 to May 2014. The three principal
recipients (PRs) are the Thai Ministry of Public Health and two non-
governmental organizations. This program aims to expand HIV
preventive services for female sex workers (FSW), people who inject
drugs (PWID), men who have sex with men (MSM), and migrant
workers. Because there was concern among PRs about the
sustainability of the program beyond the 5 years of the grant
support, the Health Intervention and Technology Assessment
Programme (HITAP) was invited by the Country Coordinating
Mechanisms (CCM) to take part alongside PRs and Sub-PRs in an
evaluation to assess the costs and cost-effectiveness of this
ongoing program. The results of this study will be used to improve
program performance and support policy decision making by the
Thai government in terms of whether and how the program
continues at the end of the period of Global Fund support.
In Myanmar, where the average number of pregnancies per year is
900,000, it is estimated that introducing the MCH voucher scheme
would increase ANC coverage from 68% to 93% and delivery by skilled-
birth attendants from 50% to 71%. The ex-ante assessment found that
the MCH voucher scheme was likely to save a significant number of
lives of mothers and infants, for whom the cost of ANC is currently
prohibitive. The assessment also found that this could be done at a
reasonable cost. The incremental costeffectiveness ratio (ICER), which in
this case is the additional cost per life-year saved from introducing the
MCH voucher scheme compared to the status quo, ranged from
376,548 to 452,110 kyats (475 kyats = 1 international dollar, in 2010). This
represents good value for money, especially given the ceiling threshold
of 1 time of GDP per capita of 413,800 kyats. The results of this study
were presented to senior decision makers in Myanmar in March 2011
resulting in an agreement being reached to implement the MCH
voucher scheme in one township commencing in November 2012
before scaling it up as a nationwide program.
Using routine administrative data, program costs and outcomes in
terms of population reached by CHAMPION were estimated in
international dollars at I$2,333/ PWID, I$270/FSW, I$162/MSM, I$161/
migrant. These estimations were much higher than the cost per person
in comparable programs for PWID in Bangladesh (I $727/PWID) and for
FSW in India (I$129/FSW). The higher costs per person in Thailand may
be explained by the shorter duration of the program (one and a half
years for CHAMPION vs. three years for the Bangladesh project, and two
years for the Indian project), which may have lead to higher fixed start-
up costs that made up a significant proportion of the overall costs per
person (a proportion which falls significantly for longer projects).
Second, and more importantly, this higher cost may be due to
Thailand’s lack of a harm reduction policy and the presence of harsh
criminal sanctions for PWID, which made it more difficult to recruit
PWID to the CHAMPION scheme. In its conclusion, the study suggests
an urgent need to improve program performance if CHAMPION is to
offer value for money in the Thai setting.
Teerawattananon et al. Globalization and Health 2013, 9:35 Page 6 of 9
http://www.globalizationandhealth.com/content/9/1/35parties involved in the delivery of external aid, and local
governments are often in a difficult situation on whether
to continue the support for initiatives previously funded
by external donors, ex-post assessments can provide good
opportunities to inform decision makers in recipient
countries about the usefulness, value for money, and other
implications the program might have if it is maintained.Challenges of using HTA for the Global Fund
There are many challenges to overcome if HTAs are to
help the Global Fund make a shift in funding projects
that have a real impact.Complexity of HTAs for the Global Fund
HTAs for the Global Fund need to be transparent, ro-
bust, and adaptable to local contexts. They also need to
take into account the local factors that may influence
the outcomes and impacts of investment. Unfortunately,
typical HTAs tend to be articulated around a single or
limited number of health interventions in a context-free
environment [41]. Because Global Fund programs often
relate to arrangements of health system and services,
and encompass multiple interventions that are packaged
together, HTAs for the Global Fund must allow for mul-
tiple interventions and outcomes being evaluated at the
same time. Global Fund HTAs should also take care to
Teerawattananon et al. Globalization and Health 2013, 9:35 Page 7 of 9
http://www.globalizationandhealth.com/content/9/1/35take into account the synergic effects of multiple inter-
vention interactions on population health as well as on
particular disease burdens. For example, HTAs could be
used to assess the synergic effects of incorporating ma-
ternal and child health activities into Global Fund pro-
grams for HIV (which is an approach that has been
recently signed off by the Global Fund Board).
Moreover, HTA should provide not only value for
money information but also social, institutional and eth-
ical implications including equity issues since different
societies may have different social values toward health
investment. For example, although expanding antiretro-
viral treatment to those eligible HIV patients but not on
it would prove to be much more costly than investing in
second or third line treatments for those failed from the
first-line regime, decision makers in particular settings
may opt to support a program to reach out the marginal
groups due to equity consideration.
HTA facilities for the Global Fund
Since the Global Fund clearly states in its mission that it
is a financing mechanism rather than an implementing
institution, it is essential that the Global Fund maintain
its role in promoting financial accountability and not de-
velop its in-house HTA capacity. Indeed, not only would
this go beyond the fund’s specific remit, it would also
create a conflict of interests in terms of eroding the sep-
aration between purchaser and provider. However, HTAs
can be expensive. A review of HTA agencies found that
the average cost per health technology assessment in ten
different countries ranges from $3,000 to $650,000 [24].
As a result, independent contracting for the provision of
technical support for HTAs might be effectively mobi-
lized through the creation of global and/or regional
HTA facilities. These HTA facilities would house the
HTA research team, reducing costs through economies
of scale, and would have the capacity to provide tech-
nical support to local staff in LICs and MICs as part of
the Global Fund’s capacity building and health system
strengthening strategy. A global HTA facility could also
be put in place to accredit regional and national HTA fa-
cilities to undertake HTA pertinent to a Global Fund
program, while also serving as a hub for the collection
of HTA-related information and advancing HTA
methods for complex interventions (The Value for
Money working group, 2013, [42-44]).
Increased investment in CCMs
Although implementation capacity is one factor that de-
termines a country’s readiness for funding, evidence
demonstrates that CCMs only used about 1% of the Glo-
bal Fund expenditure for administrative costs at their
headquarters in 2009 [45]. A 2008 paper from the Cen-
ter for Global Development notes that Local FundAgents, tasked with overseeing CCMs, lack the expertise
and capacity for program monitoring [46]. This lack of
funding may be a limiting factor for thorough reviews
and the incorporation of HTA into grant design and
proposals. This warrants improved investment in CCMs
and their partners to conduct monitoring and evalua-
tions. Increasing the placement of HTA experts in
CCMs and PRs, such as in ministries of health or minis-
tries of finance, should be considered because these ex-
perts would bring HTA knowledge and insights to the
country level and ensure the incorporation of cost-
effectiveness into all steps of grant application and
implementation.
Incentives for HTA
The Global Fund has enjoyed reputational benefits due
to its promotion of performance-based financing. It is
possible that the use of HTAs may help this reputation
to grow. Firstly, the Global Fund would be able to make
better-informed interventions, due to the evidence gar-
nered by HTAs and by complying with the HTA-
informed value for money guidance. The Global Fund is
one of the largest suppliers of antiretroviral drugs in the
world—as well a primary financier of other commodities,
including ITNs [36]. Health technologies and medicines
consume a significant portion of funds; currently almost
40% of Global Fund Grants are used for the procure-
ment and management of pharmaceuticals and health
technologies [47]. Under the current structure of the
Global Fund, the interventions funded are selected by
the PR and CCM during the proposal design process.
There is no evidence that the Global Fund in any way
limits the choice of interventions for which applicant
countries may apply. For example, there are 92 anti-
retroviral drugs on the list in different forms and dos-
ages, for a total of 309 unique items, subject to the
Global Fund Quality Assurance Policy. There are 98 ap-
proved products for tuberculosis and 29 for malaria. To-
gether, this set of over 430 possible options is not
exhaustive and PR may purchase other items as long as
the PR can determine that it would be compliant with
the quality assurance standards [48]. Clearly, the value
for money guidance issued on the back of an HTA can
be a useful tool that PRs and CCMs can use to avoid in-
vestment in high-cost and low-impact options. In
addition, the value for money guidance can be a resource
for the Global Fund (at the global level) and PRs (at the
local level) to negotiate prices with those in the industry,
by using its evidence as their guidance.
Alternatively, efforts can also be made for improving
the efficiency of performance-based payments, which
currently rely on many input indicators rather than out-
comes or impacts. The use of HTA data would allow the
fund to set standard payments per unit of output (e.g.
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reduction of unsafe sex) which are closely linked to the
final goals of the program (e.g. rate of HIV infection
averted). This ceiling on standard payments would serve
to drive substantial efficiency gains across the Global
Fund’s investment portfolio and exert pressure on other
funders to decrease their own unit costs and improve
efficiency. Countries that cannot meet the low-end unit
costs set by the Global Fund would make up the differ-
ence from other sources, leading to enhanced cost
sharing. With this option, the Global Fund can focus on
providing effective coverage of proven interventions, an
area where current monitoring and evaluation had iden-
tified significant shortfalls.
Conclusions
There is currently a new emphasis at the Global Fund and
other global health initiatives to focus on ensuring the
effective use of resources and on generating improved
value for money. This timely report proposes that
additional mechanisms, such as conducting HTAs before,
during, and after grant implementation, can help improve
the efficiency of Global Fund investment. Although some
technical and management challenges merit further inves-
tigation, the costs of delaying the use of HTA evidence-
informed investment in the Global Fund are high given the
severe disproportion between the current resources avail-
able and the need for prevention and control of three
major disease burdens worldwide.
Competing interests
With regard to ethical approval, this was not required because of the nature
of our paper. Also, the authors have no conflict of interest to declare.
Authors’ contributions
We confirm that all named authors meet the criteria of authorship. All
authors equally contributed to the course of the review and provided critical
comments to the manuscript.
Acknowledgements
This manuscript is part of the Center for Global Development’s project,
entitled “Value for Money: An Agenda for Global Health Funding Agencies,”
which received financial support from the Bill & Melinda Gates Foundation.
The funder had no role in the design, analysis, decision to publish, or
preparation of the manuscript.
The Health Intervention and Technology Assessment Program (HITAP) is
funded by the Thailand Research Fund under the Senior Research Scholar on
Health Technology Assessment (RTA5580010), the National Health Security
Office, the Thai Health Promotion Foundation, the Health System Research
Institute and the Bureau of Health Policy and Strategy, Ministry of Public
Health.
Author details
1Health Intervention and Technology Assessment Program (HITAP),
Department of Health, Ministry of Public Health, 6th floor, 6th Building,
Tiwanon Rd., Nonthaburi 11000, Thailand. 2Center for Global Development
(CGD), 1800 Massachusetts Avenue NW, Third Floor, Washington, DC 20036,
USA.
Received: 10 April 2013 Accepted: 2 August 2013
Published: 21 August 2013References
1. Kazatchkine MD: Increased resources for the Global Fund, but pledges
fall short of expected demand. Lancet 2010, 376:1439–40.
2. Mccoy D, Kinyua K: Allocating scarce resources strategically–an
evaluation and discussion of the Global Fund’s pattern of disbursements.
PLoS One 2012, 7:e34749.
3. Governance Handbook: Chapter 3 “Funding Model”. The Global Fund; 2011b.
[cited 2013 13 July]; available from http://www.theglobalfund.org/documents/
core/guides/Core_GovernanceHandbookSection3FundingModel_Handbook_en/.
4. The Value for Money Working Group: More Health for the Money: A
Practical Agenda for the Global Fund and Its Partners (Consultation
Draft). In A Report of the Center for Global Development Working Group on
Value for Money in Global Health. Edited by GLASSMAN A. Washington DC:
Center for Global Development; 2013.
5. The Global Fund: The Global Fund Strategy 2012–2016: investing for impact.
2012. [cited 2013 13 July]; available from http://www.theglobalfund.org/
documents/core/strategies/core_GlobalFund_Strategy_en/.
6. The Global Fund: Grant Portfolio: Portfolio Overview. 2013. [cited 2013 13
July]; Available from: http://portfolio.theglobalfund.org/en/Home/Index.
7. Biesma RG, Brugha R, Harmer A, Walsh A, Spicer N, Walt G: The effects of
global health initiatives on country health systems: a review of the
evidence from HIV/AIDS control. Health Policy Plan 2009, 24:239–52.
8. Katz I, Komatsu R, Low-Beer D, Atun R: Scaling up towards international
targets for AIDS, tuberculosis, and malaria: contribution of Global
Fund-supported programs in 2011–2015. PLoS One 2011, 6:e17166.
9. Feachem RG, Sabot OJ: An examination of the Global Fund at 5 years.
Lancet 2006, 368:537–40.
10. Lu C, Michaud CM, Khan K, Murray CJ: Absorptive capacity and
disbursements by the Global Fund to Fight AIDS, Tuberculosis and
Malaria: analysis of grant implementation. Lancet 2006, 368:483–8.
11. Radelet S, Siddiqi B: Global Fund grant programmes: an analysis of
evaluation scores. Lancet 2007, 369:1807–13.
12. Samb B, Evans T, Dybul M, Atun R, Moatti JP, Nishtar S, Wright A, Celletti F,
Hsu J, Kim JY, Brugha R, Russell A, Etienne C: An assessment of interactions
between global health initiatives and country health systems. Lancet
2009, 373:2137–69.
13. Piot P, Kazatchkine M, Dybul M, Lob-Levyt J: AIDS: lessons learnt and
myths dispelled. Lancet 2009, 374:260–3.
14. Brugha R, Donoghue M, Starling M, Ndubani P, Ssengooba F, Fernandes B,
Walt G: The Global Fund: managing great expectations. Lancet 2004,
364:95–100.
15. Zhao J, Lama M, Sarkar S, Atun R: Indicators measuring the performance
of malaria programs supported by the Global Fund in Asia, progress and
the way forward. PLoS One 2011, 6:e28932.
16. Martins JS, Zwi AB, Kelly PM: Did the first Global Fund grant (2003–2006)
contribute to malaria control and health system strengthening in Timor-
Leste? Malar J 2012, 11:237.
17. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M,
Jha P, Musgrove P, Chow J, Shahid-Salles S, Jamison DT: Advancement of
global health: key messages from the Disease Control Priorities Project.
Lancet 2006, 367:1193–208.
18. Bridge J, Hunter BM, Atun R, Lazarus JV: Global Fund investments in harm
reduction from 2002 to 2009. Int J Drug Policy 2012, 23:279–85.
19. Guinness L, Vickerman P, Quayyum Z, Foss A, Watts C, Rodericks A, Azim T,
Jana S, Kumaranayake L: The cost-effectiveness of consistent and early
intervention of harm reduction for injecting drug users in Bangladesh.
Addiction 2010, 105:319–28.
20. Alistar SS, Owens DK, Brandeau ML: Effectiveness and cost effectiveness of
expanding harm reduction and antiretroviral therapy in a mixed HIV
epidemic: a modeling analysis for Ukraine. PLoS Med 2011, 8:e1000423.
21. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A:
Randomized, controlled intervention trial of male circumcision for
reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005, 2:e298.
22. Avdeeva O, Lazarus JV, Aziz MA, Atun R: The Global Fund's resource
allocation decisions for HIV programmes: addressing those in need. J Int
AIDS Soc 2011, 14:51.
23. Pattanaphesaj J, Teerawattananon Y: Reviewing the evidence on
effectiveness and cost-effectiveness of HIV prevention strategies in
Thailand. BMC Public Health 2010, 10:401.
24. Korenromp EL, Glaziou P, Fitzpatrick C, Floyd K, Hosseini M, Raviglione M,
Atun R, Williams B: Implementing the global plan to stop TB, 2011–2015–
Teerawattananon et al. Globalization and Health 2013, 9:35 Page 9 of 9
http://www.globalizationandhealth.com/content/9/1/35optimizing allocations and the Global Fund’s contribution: a scenario
projections study. PLoS One 2012, 7:e38816.
25. Glassman A, Chalkidou K: Priority-Setting in Health: Building institutions for
smarter public spending. Washington, DC: The Center for Global
Development; 2012.
26. Amole C, Brisebois C, Essajee S, Koehler E, Levin A, Moore M, Ripin DB, Sickler J,
Singh I: Optimizing antiretroviral product selection: a sample approach to
improving patient outcomes, saving money, and scaling-up health services
in developing countries. J Acquir Immune Defic Syndr 2011, 57:100–3.
27. Biesma R, Makoa E, Mpemi R, Tsekoa L, Odonkor P, Brugha R: The
implementation of a Global Fund grant in Lesotho: applying a
framework on knowledge absorptive capacity. Soc Sci Med 2012,
74:381–9.
28. Desai M, Rudge JW, Adisasmito W, Mounier-Jack S, Coker R: Critical interactions
between Global Fund-supported programmes and health systems: a case
study in Indonesia. Health Policy Plan 2010, 25(Suppl 1):i43–47.
29. Hanvoravongchai P, Warakamin B, Coker R: Critical interactions between
Global Fund-supported programmes and health systems: a case study in
Thailand. Health Policy Plan 2010, 25(Suppl 1):i53–57.
30. Mangham LJ, Hanson K: Scaling up in international health: what are the
key issues? Health Policy Plan 2010, 25:85–96.
31. Mounier-Jack S, Rudge JW, Phetsouvanh R, Chanthapadith C, Coker R:
Critical interactions between Global Fund-supported programmes and
health systems: a case study in Lao People’s Democratic Republic. Health
Policy Plan 2010, 25(Suppl 1):i37–42.
32. Rudge JW, Phuanakoonon S, Nema KH, Mounier-Jack S, Coker R: Critical
interactions between Global Fund-supported programmes and health
systems: a case study in Papua New Guinea. Health Policy Plan 2010, 25
(Suppl 1):i48–52.
33. Tragard A, Shrestha IB: System-wide effects of Global Fund investments in
Nepal. Health Policy Plan 2010, 25(Suppl 1):i58–62.
34. Blaya JA, Fraser HS, Holt B: E-health technologies show promise in
developing countries. Health Aff (Millwood) 2010, 29:244–51.
35. Free C, Phillips G, Watson L, Galli L, Felix L, Edwards P, Patel V, Haines A: The
effectiveness of mobile-health technologies to improve health care
service delivery processes: a systematic review and meta-analysis. PLoS
Med 2013, 10:e1001363.
36. Report of the market dynamics and commodities ad-hoc committee: Twenty-
Third Board Meeting. Geneva, Switzerland: The Global Fund; 2011c. [cited
2013 13 July]; available from http://www.theglobalfund.org/documents/
board/23/BM23_09MDC_Report_en/.
37. Velasco Garrido M, Gerhardus A, Rottingen JA, Busse R: Developing health
technology assessment to address health care system needs. Health
Policy 2010, 94:196–202.
38. Littlejohns P, Weale A, Chalkidou K, Faden R, Teerawattananon Y: Social
values and health policy: a new international research programme. J
Health Organ Manag 2012, 26:285–92.
39. Myanmar’s Ministry of Health, World Health Organization & Health
Intervention and Technology Assessment Program: A feasibility study of the
community health initiative for maternal and child health in Myanmar. Health
Intervention and Technology Assessment Program: Nonthaburi; 2011.
40. Tosanguang K, Kingkaew P, Peerapattanapokin W, Teerawattananon Y:
Economic Evaluation of comprehensive HIV prevention interventions targeting
those most at risk of HIV/AIDs in Thailand (CHAMPION). Health Intervention
and Technology Assessment Program: Nonthaburi; 2012.
41. Perez Velasco R, Praditsitthikorn N, Wichmann K, Mohara A, Kotirum S,
Tantivess S, Vallenas C, Harmanci H, Teerawattananon Y: Systematic review
of economic evaluations of preparedness strategies and interventions
against influenza pandemics. PLoS One 2012, 7:e30333.
42. Mohler R, Bartoszek G, Kopke S, Meyer G: Proposed criteria for reporting
the development and evaluation of complex interventions in healthcare
(CReDECI): guideline development. Int J Nurs Stud 2012, 49:40–6.
43. Shiell A, Hawe P, Gold L: Complex interventions or complex systems?
Implications for health economic evaluation. BMJ 2008, 336:1281–3.
44. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P,
Spiegelhalter D, Tyrer P: Framework for design and evaluation of complex
interventions to improve health. BMJ 2000, 321:694–6.
45. Linnemayr S, Ryan GW, Liu J, Palar K: Value for Money in Donor HIV Funding.
Santa Monica, CA, RAND: Technical Report; 2011.
46. Plowman B: How the big three AIDS donors define and useperformance to inform
funding decisions. Background Paper. Center for Global Development; 2008.47. Technical Guidance Note for Global Fund HIV Proposals: Access to medicines
and health technologies and Strengthening the pharmaceutical sector
component of health systems strengthening funding requests. UNAIDS, World




48. List of Arv Pharmaceutical Products classified according to the Global Fund
Quality Assurance Policy: Version 93. Geneva, Switzerland: The Global Fund;
2012. [cited 2013 13 July]; available from http://www.theglobal fund.org/
documents/psm/PSM_ProductsHIVAIDS_List_en/.
doi:10.1186/1744-8603-9-35
Cite this article as: Teerawattananon et al.: Health technology
assessments as a mechanism for increased value for money:
recommendations to the Global Fund. Globalization and Health 2013 9:35.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
